Drugs / ABBV-467
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04178902 | May 2020 → Apr 2021 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-467 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04178902 ↗ |
| Modality | Small molecule | — CHEMBL6033457 ↗ |
| Route | Intravenous | “Intravenous (IV) Infusion” NCT04178902 ↗ |
| Target | MCL1 | “The selectivity of ABBV-467 suggests that treatment-induced troponin release is a consequence of MCL-1 inhibition” PMID 37880389 ↗ Oct 2023 |